The performance of MelaFind: A prospective multicenter study

Gary Monheit, Armand B. Cognetta, Laura Ferris, Harold Rabinovitz, Kenneth Gross, Mary Martini, James M. Grichnik, Martin Mihm, Victor G. Prieto, Paul Googe, Roy King, Alicia Toledano, Nikolai Kabelev, Maciej Wojton, Dina Gutkowicz-Krusin

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

Objective: To demonstrate the safety and effectiveness of MelaFind, a noninvasive and objective computervision system designed to aid in detection of early pigmented cutaneous melanoma. Design: A prospective, multicenter, blinded study. The diagnostic performance of MelaFind and of study clinicians was evaluated using the histologic reference standard. Standard images and patient information for a subset of 50 randomly selected lesions (25 melanomas) were used in a reader study of 39 independent dermatologists to estimate clinicians' biopsy sensitivity to melanoma. Setting: Three academic and 4 community practices in the United States with expertise in management of pigmented skin lesions. Patients: A total of 1383 patients with 1831 lesions enrolled from January 2007 to July 2008; 1632 lesions (including 127 melanomas - 45% in situ - with median Breslow thickness of invasive lesions, 0.36 mm) were eligible and evaluable for the study end points. Main Outcome Measures: Sensitivity of MelaFind; specificities and biopsy ratios for MelaFind and the study investigators; and biopsy sensitivities of independent dermatologists in the reader study. Results: The measured sensitivity of MelaFind was 98.4% (125 of 127 melanomas) with a 95% lower confidence bound at 95.6% and a biopsy ratio of 10.8:1; the average biopsy sensitivity of dermatologists was 78% in the reader study. Including borderline lesions (high-grade dysplastic nevi, atypical melanocytic proliferations, or hyperplasias), MelaFind's sensitivity was 98.3% (172 of 175), with a biopsy ratio of 7.6:1. On lesions biopsied mostly to rule out melanoma, MelaFind's average specificity (9.9%) was superior to that of clinicians (3.7%) (P=.02). Conclusion: MelaFind is a safe and effective tool to assist in the evaluation of pigmented skin lesions. Trial Registration: clinicaltrials.gov Identifier: NCT00434057.

Original languageEnglish (US)
Pages (from-to)188-194
Number of pages7
JournalArchives of Dermatology
Volume147
Issue number2
DOIs
StatePublished - Feb 1 2011

Fingerprint

Multicenter Studies
Melanoma
Prospective Studies
Biopsy
Skin
Dysplastic Nevus Syndrome
Hyperplasia
Research Personnel
Outcome Assessment (Health Care)
Safety
Dermatologists

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Monheit, G., Cognetta, A. B., Ferris, L., Rabinovitz, H., Gross, K., Martini, M., ... Gutkowicz-Krusin, D. (2011). The performance of MelaFind: A prospective multicenter study. Archives of Dermatology, 147(2), 188-194. https://doi.org/10.1001/archdermatol.2010.302

The performance of MelaFind : A prospective multicenter study. / Monheit, Gary; Cognetta, Armand B.; Ferris, Laura; Rabinovitz, Harold; Gross, Kenneth; Martini, Mary; Grichnik, James M.; Mihm, Martin; Prieto, Victor G.; Googe, Paul; King, Roy; Toledano, Alicia; Kabelev, Nikolai; Wojton, Maciej; Gutkowicz-Krusin, Dina.

In: Archives of Dermatology, Vol. 147, No. 2, 01.02.2011, p. 188-194.

Research output: Contribution to journalArticle

Monheit, G, Cognetta, AB, Ferris, L, Rabinovitz, H, Gross, K, Martini, M, Grichnik, JM, Mihm, M, Prieto, VG, Googe, P, King, R, Toledano, A, Kabelev, N, Wojton, M & Gutkowicz-Krusin, D 2011, 'The performance of MelaFind: A prospective multicenter study', Archives of Dermatology, vol. 147, no. 2, pp. 188-194. https://doi.org/10.1001/archdermatol.2010.302
Monheit G, Cognetta AB, Ferris L, Rabinovitz H, Gross K, Martini M et al. The performance of MelaFind: A prospective multicenter study. Archives of Dermatology. 2011 Feb 1;147(2):188-194. https://doi.org/10.1001/archdermatol.2010.302
Monheit, Gary ; Cognetta, Armand B. ; Ferris, Laura ; Rabinovitz, Harold ; Gross, Kenneth ; Martini, Mary ; Grichnik, James M. ; Mihm, Martin ; Prieto, Victor G. ; Googe, Paul ; King, Roy ; Toledano, Alicia ; Kabelev, Nikolai ; Wojton, Maciej ; Gutkowicz-Krusin, Dina. / The performance of MelaFind : A prospective multicenter study. In: Archives of Dermatology. 2011 ; Vol. 147, No. 2. pp. 188-194.
@article{2984a94cb149440691b599ea0b3de69b,
title = "The performance of MelaFind: A prospective multicenter study",
abstract = "Objective: To demonstrate the safety and effectiveness of MelaFind, a noninvasive and objective computervision system designed to aid in detection of early pigmented cutaneous melanoma. Design: A prospective, multicenter, blinded study. The diagnostic performance of MelaFind and of study clinicians was evaluated using the histologic reference standard. Standard images and patient information for a subset of 50 randomly selected lesions (25 melanomas) were used in a reader study of 39 independent dermatologists to estimate clinicians' biopsy sensitivity to melanoma. Setting: Three academic and 4 community practices in the United States with expertise in management of pigmented skin lesions. Patients: A total of 1383 patients with 1831 lesions enrolled from January 2007 to July 2008; 1632 lesions (including 127 melanomas - 45{\%} in situ - with median Breslow thickness of invasive lesions, 0.36 mm) were eligible and evaluable for the study end points. Main Outcome Measures: Sensitivity of MelaFind; specificities and biopsy ratios for MelaFind and the study investigators; and biopsy sensitivities of independent dermatologists in the reader study. Results: The measured sensitivity of MelaFind was 98.4{\%} (125 of 127 melanomas) with a 95{\%} lower confidence bound at 95.6{\%} and a biopsy ratio of 10.8:1; the average biopsy sensitivity of dermatologists was 78{\%} in the reader study. Including borderline lesions (high-grade dysplastic nevi, atypical melanocytic proliferations, or hyperplasias), MelaFind's sensitivity was 98.3{\%} (172 of 175), with a biopsy ratio of 7.6:1. On lesions biopsied mostly to rule out melanoma, MelaFind's average specificity (9.9{\%}) was superior to that of clinicians (3.7{\%}) (P=.02). Conclusion: MelaFind is a safe and effective tool to assist in the evaluation of pigmented skin lesions. Trial Registration: clinicaltrials.gov Identifier: NCT00434057.",
author = "Gary Monheit and Cognetta, {Armand B.} and Laura Ferris and Harold Rabinovitz and Kenneth Gross and Mary Martini and Grichnik, {James M.} and Martin Mihm and Prieto, {Victor G.} and Paul Googe and Roy King and Alicia Toledano and Nikolai Kabelev and Maciej Wojton and Dina Gutkowicz-Krusin",
year = "2011",
month = "2",
day = "1",
doi = "10.1001/archdermatol.2010.302",
language = "English (US)",
volume = "147",
pages = "188--194",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - The performance of MelaFind

T2 - A prospective multicenter study

AU - Monheit, Gary

AU - Cognetta, Armand B.

AU - Ferris, Laura

AU - Rabinovitz, Harold

AU - Gross, Kenneth

AU - Martini, Mary

AU - Grichnik, James M.

AU - Mihm, Martin

AU - Prieto, Victor G.

AU - Googe, Paul

AU - King, Roy

AU - Toledano, Alicia

AU - Kabelev, Nikolai

AU - Wojton, Maciej

AU - Gutkowicz-Krusin, Dina

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Objective: To demonstrate the safety and effectiveness of MelaFind, a noninvasive and objective computervision system designed to aid in detection of early pigmented cutaneous melanoma. Design: A prospective, multicenter, blinded study. The diagnostic performance of MelaFind and of study clinicians was evaluated using the histologic reference standard. Standard images and patient information for a subset of 50 randomly selected lesions (25 melanomas) were used in a reader study of 39 independent dermatologists to estimate clinicians' biopsy sensitivity to melanoma. Setting: Three academic and 4 community practices in the United States with expertise in management of pigmented skin lesions. Patients: A total of 1383 patients with 1831 lesions enrolled from January 2007 to July 2008; 1632 lesions (including 127 melanomas - 45% in situ - with median Breslow thickness of invasive lesions, 0.36 mm) were eligible and evaluable for the study end points. Main Outcome Measures: Sensitivity of MelaFind; specificities and biopsy ratios for MelaFind and the study investigators; and biopsy sensitivities of independent dermatologists in the reader study. Results: The measured sensitivity of MelaFind was 98.4% (125 of 127 melanomas) with a 95% lower confidence bound at 95.6% and a biopsy ratio of 10.8:1; the average biopsy sensitivity of dermatologists was 78% in the reader study. Including borderline lesions (high-grade dysplastic nevi, atypical melanocytic proliferations, or hyperplasias), MelaFind's sensitivity was 98.3% (172 of 175), with a biopsy ratio of 7.6:1. On lesions biopsied mostly to rule out melanoma, MelaFind's average specificity (9.9%) was superior to that of clinicians (3.7%) (P=.02). Conclusion: MelaFind is a safe and effective tool to assist in the evaluation of pigmented skin lesions. Trial Registration: clinicaltrials.gov Identifier: NCT00434057.

AB - Objective: To demonstrate the safety and effectiveness of MelaFind, a noninvasive and objective computervision system designed to aid in detection of early pigmented cutaneous melanoma. Design: A prospective, multicenter, blinded study. The diagnostic performance of MelaFind and of study clinicians was evaluated using the histologic reference standard. Standard images and patient information for a subset of 50 randomly selected lesions (25 melanomas) were used in a reader study of 39 independent dermatologists to estimate clinicians' biopsy sensitivity to melanoma. Setting: Three academic and 4 community practices in the United States with expertise in management of pigmented skin lesions. Patients: A total of 1383 patients with 1831 lesions enrolled from January 2007 to July 2008; 1632 lesions (including 127 melanomas - 45% in situ - with median Breslow thickness of invasive lesions, 0.36 mm) were eligible and evaluable for the study end points. Main Outcome Measures: Sensitivity of MelaFind; specificities and biopsy ratios for MelaFind and the study investigators; and biopsy sensitivities of independent dermatologists in the reader study. Results: The measured sensitivity of MelaFind was 98.4% (125 of 127 melanomas) with a 95% lower confidence bound at 95.6% and a biopsy ratio of 10.8:1; the average biopsy sensitivity of dermatologists was 78% in the reader study. Including borderline lesions (high-grade dysplastic nevi, atypical melanocytic proliferations, or hyperplasias), MelaFind's sensitivity was 98.3% (172 of 175), with a biopsy ratio of 7.6:1. On lesions biopsied mostly to rule out melanoma, MelaFind's average specificity (9.9%) was superior to that of clinicians (3.7%) (P=.02). Conclusion: MelaFind is a safe and effective tool to assist in the evaluation of pigmented skin lesions. Trial Registration: clinicaltrials.gov Identifier: NCT00434057.

UR - http://www.scopus.com/inward/record.url?scp=79951998812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951998812&partnerID=8YFLogxK

U2 - 10.1001/archdermatol.2010.302

DO - 10.1001/archdermatol.2010.302

M3 - Article

C2 - 20956633

AN - SCOPUS:79951998812

VL - 147

SP - 188

EP - 194

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 2

ER -